AUCTORES
Globalize your Research
Case Report | DOI: https://doi.org/10.31579/2690-4861/481
Department of Medical Oncology, Université de Genève, Hôpitaux Universitaires de Genève, Geneva 1205, Switzerland.
*Corresponding Author: Lorenzo Francini, Department of Medical Oncology, Université de Genève, Hôpitaux Universitaires de Genève, Geneva 1205, Switzerland.
Citation: Lorenzo Francini, Rita Brito, Eugenio Fernandez, Petros Tsantoulis and Daniele Frisone, (2024), Impressive response to Pralseltinib in KIAA1468 RET-fusion anaplastic thyroid cancer: a case report and literature review, International Journal of Clinical Case Reports and Reviews, 18(1); DOI:10.31579/2690-4861/481
Copyright: © 2024, Lorenzo Francini. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 25 May 2024 | Accepted: 03 June 2024 | Published: 19 June 2024
Keywords: RET fusion; pralsetinib; selpercatinib; anaplastic thyroid cancer; KIAA1468-RET fusion
Anaplastic thyroid carcinoma (ATC) is a severe, aggressive form of cancer with low survival rates. Multimodal therapies are currently employed with limited success and targeting molecular subgroups of ATC, such as those with RET translocation, is an active area of research.
In this case report, we present a patient with metastatic ATC harboring a RET translocation, treated with two RET-specific tyrosine kinase inhibitors (TKIs), Pralsetinib and Selpercatinib. Pralsetinib resulted in a significant and rapid reduction in lung metastasis complicated by a pneumothorax effects.
The initial efficacy of Pralsetinib in our patient underscores the potential of RET-specific TKIs in the management of RET-altered ATC and highlights the risk of adverse events associated with tumor response in high tumor burden diseases. Meticulous management of side effects remains essential to improve patient outcomes.
Anaplastic thyroid carcinoma (ATC) is an undifferentiated tumor of the follicular epithelium of the thyroid. It represents 1-2 % of thyroid malignancies and is one of the most aggressive malignancies. Its incidence in Europe is stable over time (< 0.3/100,000) [1]. It is more frequent in older age with a higher prevalence in the femalesex and in areas of endemic goiter.About 80% of patients have locally advanced disease at diagnosis, and almost half have distant metastases, especially in lung, bone, and brain. The median survival from diagnosis is 5 months and less than 20% of patients survive at 1 year [2].
It is assumed that ATC derives from well-differentiated thyroid cancer as papillary thyroid cancer following a carcinogenic multistep process. This is supported by a coexisting or a history of well- differentiated thyroid cancer in patients with an ATC. Moreover, mutations in BRAF and RAS genes are the most frequent alterations observed in both PTC and ATC. In the opposite TP53, TERT promoter and PI3K mutations are much more frequent in ATC than PTC and seem therefore essential for anaplastic transformation from PTC [3-6]. NTRK is another possible target in thyroid cancer, with a general frequency of rearrangement of about 3% of all thyroid carcinomas [7]. A pooled analysis of 28 patients with NTRK fusion-positive thyroid cancer across two trials of larotrectinib, including 7 with ATC showed an ORR of 29% in this population [8].
RET rearrangement is observed in 4-7% of non-medullary differentiated thyroid cancers but are relatively rare in ATC [9] [14-16]. RET fusion-positive thyroidcancers are associated with more frequent recurrence and shorter survival. Twenty-four different RET fusions are identified in RET fusion-positive thyroid cancer with CCD6-RET and NCOA4-RET being the most frequent [18]. RET fusions result in a RET protein with a constitutive tyrosine kinase domain activation and oncogenesis [10].
RET encodes a transmembrane receptor protein with an intracellular tyrosine kinase domain that is involved in the MAPK and PI3K-AKT signaling pathways [12,13]. There are two main categories of RET abnormalities: point mutations and RET gene fusions. Point mutations are primarily found in the kinase and cysteine-rich domains and observed in sporadic or in MEN2 syndrome associated medullary thyroid cancer (MTC) [7,8].
Selective RET thyrosine kinase inhibitors (TKI) are an effective approach for RET-driven tumors since 2010. While Lenvatinib and Sorafenib for DTC, and Cabozantinib and Vandetanib for MTC are all treatments FDA approved in case of progressive diseases, with a significant increase of PFS, they have not been proved useful ATC [7].
Selpercatinib and Pralsetinib are both potent, orally bioavailable selective RET-specific TKI with a similar action on docking the ATP-binding pocket [19]. The LIBRETTO-001 phase I/II trial assessed the selpercatinib overall response rate in patientswith thyroid tumorsharboring a RET abnormality. In RET fusion-positive thyroid cancer subgroup (19 patients), the response rate was 79% and 1-year progression-free survival was 64% [16]. In the ARROW multicohort phase I/II trial, a response was reported in 8 of 9 RET fusion-positive thyroid cancer (89%) treated with pralsetinib [6]. In these two pivotal studies, ATC were substantially under-represented 2 cases with RET fusion in LIBRETTO 001 and no cases in ARROW trial) [15]. The two cases described reported a remarkable response lasting 18 et 19 months respectively [14,17].
We present here the case of an 84-year-old woman who experienced sudden onset of dysphonia in September 2022. She described a decline in appetite, and physical examination revealed a palpable mass in the left cervical region. Initial imaging with a CT-scan showed a substantial thyroid tumor on the left side, which was invading the proximal oesophagus.Additionally, approximately 30 pulmonary metastases were identified with the biggest measuring more than 7 cm. There was no evidence of metastases in either the bone or abdominal regions. A surgical thyroid biopsy confirmed the diagnosis of metastatic anaplastic thyroid cancer resulting from a papillary thyroid cancer (Figure 1).
Figure 1: Component of anaplastic thyroid carcinoma (left) and papillary carcinoma (right)
After discussion with the patient, we administered decompressive radiotherapy for complete dysphagia at a dose of 70 Gy (2 Gy/d for 35 days) until 30.11.2022, with minimal clinical benefit leading to gastrostomy placement.
Molecular analysis identified a RET translocation (KIAA1468-RET fusion) associated with TP 53 (p. Glu286Lys) and NOTCH2 (p. Pro6ArgfsTer27) pathogenic mutations. No BRAF, RAS or TERT mutations were observed andDNA mismatch repair proteins were preserved (PMS2, MLH1, MSH2 et MSH6). Based on these results, we started a treatment with Pralsetinib administered through percutaneous endoscopic gastrostomy starting on the 28th of December 2022. During the 2 weeks following the treatment introduction, we observed a rapid favourable evolution with an improvement of dysphonia and dysphagia and a subjective size reduction of the thyroid mass.
On January 24th, one month after the treatment introduction, the patient described an acute dyspnea with a hypoxia while breathing ambient air. A CT-scan showed a right pneumothorax and pulmonary lung metastasis shrinkage and excavation. The pneumothorax was deemed secondary to lung metastasis necrosis and excavation (Figure 2). Pneumothorax was treated by chest tube placement and a pleurodesis. Subsequently the patient presented numerous complications, possibly linked to the oncological treatment, specifically a bacterial pneumonia with Klebsiella Pneumoniae and Pseudomonas Aeruginosa complicated by a heart failure and a Herpes simplex 1 stomatitis. For this reason, Pralsetinib was suspended from 27.01.2023 to 01.02, then reintroduced from 02.02 to 06.02.2023. Since a co-existing drug-induced pneumonitis could not be excluded, given the clinical improvement following the introduction of corticosteroids and CT imaging, the treatment was stopped on the 07.02.2023.
Figure 2: Right pneumothorax secondary to necrosis and reduction of pulmonary metastasis after 1 month on Pralsetinib
A thoracic CT scan performed on 28.02.2023 showed a resolution of the ground glass infiltrates but, on the other hand, oncological disease progression with an increase in size of multiple nodules and necrotic central lung masses.
Due to different toxicity profile, the initial target treatment was replaced by Selpercatinib, another receptor tyrosine kinase RET inhibitor, that was started on 01.03.2023 twice daily 160mg. After a rehabilitation period, the patient could be discharged in April 2023, but deceased after one month for undetermined reasons.
In our case, Pralsetinib administered by gastrostomy was highly effective, leading to a rapid shrinkage of target lesions easily visible on a simple chest X-ray (Figure 3) and confirmed at CT scan (Figure 2).
The RET fusion identified in our study is rare, previously described in only one other article [20].
Figure 3: Chest x-ray. Shrinkage of lung metastasis during the first month of Pralsetinib
After a relatively brief pause with the first RET inhibitor, Pralsetinib, the disease progressed rapidly (Figure 4), and another biopsy was not clinically indicated. The introduction of a second RET inhibitorfailed to elicit a clinical response, and we lack insights into the resistance mechanisms that could have led to this progression upon rechallenge with a second RET inhibitor. Although literature on this topic is limited, analyses of case series in thyroid and non-small cell lung cancers [21] suggest that additional RET mutations or MAPK pathway activation at various levels are the primary mechanisms of resistance [22].
Figure 4: Chest x-ray. Progression of lung metastases after 1 month without RET inhibitors
In an area scarcely covered in the medical literature, we aimed to present our case to highlight the remarkable effectiveness of RET inhibitors in such scenarios, demonstrating significant tumor reduction alongside notable serious complications that must be addressed. Our literature review and case study revealed multiple insights.
A dose-escalation (“ramp-up”) strategy for initiating RET inhibitors may offer a viable approach for patients with extensive tumor burden. This personalized dosing method could provide a safer and more effective treatment administration, underscoring the need for adaptable therapeutic strategies in managing RET-rearranged anaplastic thyroid cancer.
To our knowledge, this is the first documented instance of using RET inhibitors through a gastrectomy, and this administration method has shown effectiveness.
However, there remains much to understand about overcoming resistance to RET inhibitors. Due to the rarity of this condition, a definitive treatment algorithm has not been developed, and other targeted therapies do not appear universally effective.
This case underscores the need for ongoing research and multidisciplinary efforts to optimize treatment strategies for patients with RET-rearranged cancers.
We thank the patient and her family for accepting publication of this case report in an anonymous way, contributing to science developing in this field.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
